Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
| Last: | $40.08 |
|---|---|
| Change Percent: | -3.56% |
| Open: | $40.22 |
| Close: | $41.56 |
| High: | $40.54 |
| Low: | $39.2 |
| Volume: | 308,128 |
| Last Trade Date Time: | 03/12/2026 12:45:53 pm |
| Market Cap: | $2,603,991,883 |
|---|---|
| Float: | 65,619,664 |
| Insiders Ownership: | 1.61% |
| Institutions: | 44 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.spyre.com |
| Country: | US |
| City: | Waltham |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Spyre Therapeutics Inc. (NASDAQ: SYRE).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
